Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biochem Pharma (BCHE) -- Ignore unavailable to you. Want to Upgrade?

To: Aggie who wrote (621)	4/30/1999 3:11:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 783

I'm not sure about the timing or the content of the referenced reports. Recently, the Fed. accn'ting bd approved changes in the "pooling" method by which mergers are paid for with a one-time charge rather than taken over many (40) years [and therefor diluting future earnings]. Here are several links to articles that talk about this change. Message 9069410 Message 9083270 These proposed changes are not going to start for some time. I do not know if that is what was inferred to in that comment. IMHO, the problems with GLX production could further impact the price, but the downgrades based on only 1Qtr sales seem out of line. Interestingly, one group had the HBV revenue at $6M, another at $10M, when in fact the number was $800K. Quite a disparity in anticipated $'s. I guess if I projected $10M and they did less than 10% of that, I'd have to scale back my projections , and therefor ratings, just to save face. Jim